Antiretroviral Therapy Initiation Alters the Redox System of Asymptomatic HIV-Infected Individuals: A Longitudinal Study
Table 2
Vitamin profile of 30 PLWHA before (M0) and after (M1) cART initiation.
Variables
M0 (MEAN ± SD)
M1 (MEAN ± SD)
value
Lutein (μmol/mL)
0.06 ± 0.06
0.05 ± 0.04
Ns
G1
0.06 ± 0.06
0.05 ± 0.04
Ns
G2
0.06 ± 0.04
0.04 ± 0.03
0.018
Cryptoxanthin (μmol/mL)
0.08 ± 0.09
0.07 ± 0.07
Ns
G1
0.07 ± 0.05
0.07 ± 0.08
Ns
G2
0.15 ± 0.14
0.07 ± 0.05
Ns
β-Carotene (μmol/mL)
0.31 ± 0.39
0.17 ± 0.12
<0.0001
G1
0.28 ± 0.36
0.15 ± 0.10
0.002
G2
0.31 ± 0.44
0.18 ± 0.17
0.001
Lycopene (μmol/mL)
0.66 ± 0.47
0.44 ± 0.24
0.015
G1
1.94 ± 3.98
0.45 ± 0.22
Ns
G2
0.86 ± 0.58
0.32 ± 0.26
0.019
α-Tocopherol (μmol/mL)
17.94 ± 8.37
4.14 ± 5.72
0.005
G1
15.82 ± 8.52
4.29 ± 5.85
0.030
G2
18.78 ± 10.53
3.85 ± 6.19
0.048
Retinol (μmol/mL)
2.83 ± 1.42
1.82 ± 0.49
0.002
G1
2.47 ± 1.41
1.86 ± 0.51
Ns
G2
2.78 ± 1.75
1.36 ± 0.48
Ns
PLWHA: people living with HIV/AIDS; cART: combined antiretroviral therapy; G1- CD4+ T counts <500, ; G2- CD4+ T >500 cells/mL (considering the counts in M0), ; SD: standard deviation; Ns: no significant values;analysis of the 30 total patients without division into groups. Statistical tests: ANOVA with post hoc Tukey tests for retinol and Gamma Distribution for the other variables.
